^
    1m
    Current status and future potential of CD123-based targeted therapies for acute leukemia. (PubMed, Expert Opin Biol Ther)
    It discusses completed and ongoing clinical trials for agents such as tagraxofusp, pivekimab sunirine, flotetuzumab, vibecotamab, and investigational CAR T-cell therapies (e.g. MB-102, UCART123v1.2). While clinical activity has been demonstrated, especially in BPDCN, therapeutic durability and safety remain hurdles. Precision in antigen targeting, combination strategies, and toxicity management will be critical for successful integration of CD123-directed therapies into standard clinical practice.
    Review • Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    flotetuzumab (MGD006) • Elzonris (tagraxofusp-erzs) • pivekimab sunirine (PVEK) • UCART123 • vibecotamab (XmAb14045) • MB-102
    over1year
    Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (clinicaltrials.gov)
    P=N/A, N=3, Terminated, Mustang Bio | N=331 --> 3 | Trial completion date: Jul 2041 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Apr 2041 --> Apr 2024; Business Reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    MB-106 • MB-102
    2years
    Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. (PubMed, Mol Ther Oncolytics)
    The CD33/CD123 bispecific CAR T cells were able to control acute myeloid leukemia (AML) in a xenograft AML mouse model similar to monospecific CD33 and CD123 CAR T cells while showing no on-target off-tumor effects. Based on our findings, human CD33/CD123 bispecific CAR T cells are a promising cell-based approach to prevent AML and support clinical investigation.
    Journal • CAR T-Cell Therapy
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 expression • IL3RA expression
    |
    MB-102
    3years
    Significantly Targeting Acute Myeloid Leukemia with the Combination of Anti-CD123 CAR Modified Expanded Natural Killer Cells and Romidepsin (TCT-ASTCT-CIBMTR 2023)
    Results Anti-CD123 CAR expressed on more than 96% of expanded NK cells after CAR mRNA electroporation (Fig.1A) and lasted for about one week. Anti-CD123 CAR NK showed significantly enhanced in vitro cytotoxicity against CD123 + KG1a and HL-60 with significantly enhanced IFN-
    IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • NKG2D (killer cell lectin like receptor K1)
    |
    CD123 expression
    |
    Istodax (romidepsin) • MB-102
    5years
    Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov)
    P1, N=42, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive
    |
    fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102
    6years
    Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov)
    P1, N=42, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2019 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Nov 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive
    |
    fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102